author-photo

Gergana Galabova

13

Papers

258

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.

2021 European Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (2)
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.

2021 Journal of Parkinson's disease
Show All
- Source
- Cite
- Save
Citations (3)
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.

2020 Lancet Neurology
Show All
- Source
- Cite
- Save
Citations (34)
Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies–like model

2019 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (8)
Affitope-based anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) vaccine (AT04A) reduces atherosclerosis in APOE*3Leiden.CETP mice

2016 Atherosclerosis
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 15205: Atheroprotective Effect of the AFFITOPE®-based Anti-PCSK9 Vaccine (AT04A) in APOE*3Leiden.CETP Mice

2015 Circulation
Show All
- Source
- Cite
- Save
Citations (0)
759 PEPTIDE-BASED IMMUNIZATION AGAINST PCSK9 REDUCES TOTAL CHOLESTEROL IN MICE

2011 Atherosclerosis Supplements
Show All
- Source
- Cite
- Save
Citations (0)